Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That has been the case for like 2 years now... I have faith in the science and I believe ADXS will deliver its value some day...
I'm willing to wait it out all the way to 2022 when ADXS hits market...
I saw the $19 price target somewhere a couple of days ago...
But NASDAQ still got $23, so I'm going to believe NASDAQ over others...
See link below:
http://www.nasdaq.com/symbol/adxs/analyst-research
Lol @ only 5 and 11 shares being trades taking place at a time for ADXS...
People are done selling! Let's go up up & away!!'
"Conditions of Accelerated Approval
1. Promotional Materials
Unless otherwise informed by the Agency, an applicant must submit to the Agency for consideration during the preapproval review period copies of all promotional materials, including promotional labeling as well as advertisements, intended for dissemination or publication within 120 days following marketing approval.29 After 120 days following marketing approval, unless otherwise informed by the Agency, the applicant must submit promotional materials at least 30 days prior to the intended time of initial dissemination of the labeling or initial publication of the advertisement.30
2. Confirmatory Trials
For drugs granted accelerated approval, postmarketing confirmatory trials have been required to verify and describe the anticipated effect on IMM or other clinical benefit. These trials must be completed with due diligence.31
FDA has interpreted the due diligence requirement to mean that the postmarketing trial(s) intended to verify the clinical benefit must be conducted promptly to facilitate determination, as soon as possible, of whether clinical benefit has been verified. The protocol for a postmarketing trial should be developed as early as possible, and timelines for the trial should be specified; for example, timelines for enrollment and trial completion should be stipulated. There should be agreement between FDA and the sponsor on the design and conduct of the confirmatory trial(s).
If it is clear during development that a product is intended to be approved under accelerated approval on the basis of a surrogate endpoint or an intermediate clinical endpoint, confirmatory trial(s) should be underway at the time the marketing application is submitted. If it is not clear until shortly before or after submission of a marketing application that a surrogate endpoint or an intermediate clinical endpoint will be the proposed basis for accelerated approval, there should be agreement on the design and conduct of such trial(s) before approval.
Generally, the confirmatory trial would evaluate a clinical endpoint that directly measures clinical benefit. For example, the confirmatory trial population would ordinarily be the same disease population that was studied to support accelerated approval. In some cases, however, the commercial availability of a drug following accelerated approval may make it difficult to enroll patients in the same disease population. In these cases, a confirmatory trial may be conducted in"
Correction on first paragraph:
It's "without buying ADXS" instead of "with buying ADXS"...
Smartphone error
Amgen was smart... they essentially bought the ADXS Core (NEO) to treat all kinds of cancers with buying ADXS...
Amgen was a good deal cuz ADXS needed cash
Likewise, Amgen was a bad deal cuz buyers will be turned off ADXS cuz of the Amgen deal... therefore ADXS logical route is more and more partnerships and licensing the different LM varieties with different combinations....
Closing green on low volume suggests that shorts are at all time high if 10 million and are simply covering some back...
Why are people thinking of news this week? ADXS does whatever we can't think of...
So I forecast so news this week just because everyone is speculating news this week from thin air...
I would like the message as Lombardo is a temporary CEO... prove your worth by delivering shareholder value and come permanent CEO...
That would work best! And Management doesn't really have to announce anything
Agreed, spot on. And thanks for post, always good to hear from long time followers
But ADXS isn't even part of the IBB index...
The mouse ran down the clock?
No wait.. OWCP ran down the clock? Hmmmm...
Maple, can you please tell us what Justice and China is about? I don't know about these...
So this may be a repeat, but very important to reiterate and is going to be the highlight for ESGO in November for ADXS:
GOG trail at 38% (the best) has potential to go up to 77% based on genetic biomarkers!!!
"In the GOG/NRG-0265 Phase 2 trial (NCT01266460), patients with persistent or recurrent metastatic carcinoma of the cervix treated with axal were 77 percent more likely to survive if they had low serum levels of a cluster of four proteins at the study’s start."
"Results from this trial showed a strong correlation between levels of four specific proteins and overall survival. The patients were stratified according to the levels of the four proteins in each patient. The first group of 25 patients had relatively low levels of all four proteins, and had an overall survival of 56%. The second group of 20 patients had relatively high levels of all four proteins, and had an overall survival of 15%. The 12-month overall survival of all patients in this trial was 38%."
Source:
https://immuno-oncologynews.com/2017/06/29/blood-protein-levels-may-identify-cervical-cancer-patients-likely-benefit-advaxis-drug-candidate/
I like ADXS holding up nicely on a negative day for biotech in general cuz the healthcare vote got delayed by a week.
Hoping for a close above $7 though, that will become a good support number.
Yeah, I didn't realize such a high O/S size until recently to be honest... and the scary part is that it keeps going up.
But based on the response you gave and recent progress HEMP has made... I think HEMP is a good play to watch out for the next 6 to 12 months...
I got in at 0.027 if I remember correctly... and I am willing to wait it out until the next year
Thanks for your insight Digdough.
Digdough, what do you think of the ongoing dilution with HEMP and continued fall of the share price?
Thanks, good link.
Another private paid report... and ADXS is a key player mentioned in it! I am liking this...
Global Vaccines Market 2017 - Industry Analysis, Size, Share and Forecast to 2022
Read more: http://m.digitaljournal.com/pr/3413455#ixzz4n5p6fODU
Thanks for the Video Chart Clay... it's been a while
Thanks ClayTrader... good post..
It's been a while since you did a review on ADXS, I missed your reviews :)
The unfortunate thing is that I have been following the 200-day moving average for a long long time...
ADXS just can't break past it.. every single time ADXS touches the 200-Day moving average, there is a sharp drop
So much drama between AZN and TEVA today... in the morning there was news that AZN CEO is leaving to joint TEVA...
Now there is news that AZN CEO is staying out and not leaving....
Must be a money making scheme played in the background?
Can this post by Condor be saved in the sticky list please?
Thanks for the reaching out and posting back to the board.
You Da Man PoopMan!
Agreed, Dew gave some good insight and only pointed to the possibility of second shoe drop...
enjoy and appreciate the green today.... no need for cynicism on a Green Day!
Everyone should be happy about the green color at lunch time which is statistically red 99.999% if the time
So guys, ADXS BROKE PAST $7 :)
Astra CEO got us leaving Astra to work for TEVA...
Also, they got a trail update coming up in like a month on some immunocancer....
I smell trouble....
Good riddance from ADXS I say
So where's the surprise?
How confident is this surprise? Should buy some more?
This may not be apple... but ADXS is certainly synonymous to Microsort...
ADXS is the operating systems on which different programs will be used to cure different cancers!
The kind of returns $$$$ ADXS can provide... this should be atleast $50 right now
Can anyone please tell me why OWCP fell? I didn't keep up the last month...
There was a time when I was waiting for ADXS to fall so I could get in... and it went all the way to $30....
When the real ADXS rise starts this time... it's gonna touch $50!
I don't believe my eyes @_@
ADXS is green at lunch time? Someone pinch me...
Good point that he is not made permanent.... maybe the board wanna see him deliver some value before Lombardo becomes permanent...
I would love for this scenario to be true.
Just sharing info on Lombardo... he mad old ... 70 lol
"Mr. Lombardo, 70, currently serves as the Chief Business Officer and Senior Vice President of the Company. He is an accomplished industry veteran with nearly 30 years of leadership experience in the life sciences industry. Prior to joining Advaxis in April 2017, Mr. Lombardo was a Partner at The Channel Group, where, from 2014 to 2017 he provided strategic advisory services to biotechnology, pharma and med-tech companies. Previously, beginning in 2000, he was President and CEO of E-Z-EM Inc., which was sold to Bracco Diagnostics in 2008, where Mr. Lombardo remained and oversaw business operations for six years as the Chief Operating Officer. Prior to joining E-Z-EM, Lombardo served as the President of ALI Imaging Systems, Inc., which was sold to McKesson in 2002. He has also held leadership roles at General Electric Medical Systems, Philips Medical Systems, Loral/Lockheed Martin Corp. and Sony Corporation."
I bought during the sharp fall last month... maybe that was the time when insider connections knew of DIC's leave in the works... and did some panic sell off / shorting...
Maybe I will nibble more this week
I though $0.02 would be the floor for HEMP... but it fell below... hopefully it will bounce up...
The positive news don't seem to have impact on price these days?